Beata Korytowsky

1.7k total citations
78 papers, 1.1k citations indexed

About

Beata Korytowsky is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Beata Korytowsky has authored 78 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 48 papers in Oncology and 21 papers in Economics and Econometrics. Recurrent topics in Beata Korytowsky's work include Lung Cancer Treatments and Mutations (26 papers), Lung Cancer Research Studies (17 papers) and Economic and Financial Impacts of Cancer (17 papers). Beata Korytowsky is often cited by papers focused on Lung Cancer Treatments and Mutations (26 papers), Lung Cancer Research Studies (17 papers) and Economic and Financial Impacts of Cancer (17 papers). Beata Korytowsky collaborates with scholars based in United States, United Kingdom and France. Beata Korytowsky's co-authors include Robert J. Motzer, Xun Lin, Ewa Matczak, Robin Wiltshire, M.J. Lechuga, Ana M. Molina, Robert A. Figlin, David Cella, Olga Valota and Hariharan Subramanian and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Beata Korytowsky

74 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beata Korytowsky United States	17	617	565	370	250	130	78	1.1k
Olga Valota Italy	14	563 0.9×	346 0.6×	436 1.2×	258 1.0×	55 0.4×	43	891
Pallavi S. Mishra‐Kalyani United States	22	560 0.9×	883 1.6×	332 0.9×	191 0.8×	112 0.9×	49	1.5k
Luca Moscetti Italy	20	873 1.4×	1.1k 2.0×	355 1.0×	361 1.4×	53 0.4×	98	1.6k
Eduard Vrdoljak Croatia	15	617 1.0×	435 0.8×	465 1.3×	308 1.2×	68 0.5×	78	1.2k
Kosj Yamoah United States	19	791 1.3×	433 0.8×	228 0.6×	293 1.2×	109 0.8×	102	1.4k
Sylvie Négrier France	15	578 0.9×	342 0.6×	481 1.3×	334 1.3×	73 0.6×	37	883
Yoshiko Umeyama Japan	16	554 0.9×	490 0.9×	263 0.7×	146 0.6×	35 0.3×	35	813
Angel H. Bair United States	13	704 1.1×	435 0.8×	559 1.5×	330 1.3×	116 0.9×	17	1.0k
D.Y.C. Heng Canada	18	652 1.1×	372 0.7×	400 1.1×	314 1.3×	68 0.5×	55	927
Aly‐Khan A. Lalani Canada	19	837 1.4×	695 1.2×	467 1.3×	367 1.5×	79 0.6×	88	1.3k

Countries citing papers authored by Beata Korytowsky

Since Specialization

Citations

This map shows the geographic impact of Beata Korytowsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beata Korytowsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beata Korytowsky more than expected).

Fields of papers citing papers by Beata Korytowsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beata Korytowsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beata Korytowsky. The network helps show where Beata Korytowsky may publish in the future.

Co-authorship network of co-authors of Beata Korytowsky

This figure shows the co-authorship network connecting the top 25 collaborators of Beata Korytowsky. A scholar is included among the top collaborators of Beata Korytowsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beata Korytowsky. Beata Korytowsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Danese, Mark D., et al.. (2025). Imaging Utilization and Treatment Patterns of Brain Metastases in Patients With Non-Small Cell Lung Cancer: A SEER-Medicare and SEER Database Analysis. Clinical Lung Cancer. 26(7). 552–563.e5.

Korytowsky, Beata, et al.. (2024). Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis. Lung Cancer. 193. 107854–107854. 1 indexed citations

Lu, Shun, Fabrice Barlési, Robert M. Jotte, et al.. (2024). OA09.06 Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12. Journal of Thoracic Oncology. 19(10). S30–S30. 2 indexed citations

Korytowsky, Beata, et al.. (2023). CO95 Matching-Adjusted Indirect Comparison (MAIC) in Previously Treated KRAS G12C-Mutated Advanced/Metastatic Non-Small Cell Lung Cancer (a/mNSCLC): Adagrasib Versus Sotorasib. Value in Health. 26(12). S31–S31. 2 indexed citations

Korytowsky, Beata, et al.. (2023). EE357 Cost per Responder Analysis Comparing Adagrasib and Sotorasib in Patients With KRAS G12C-Mutated Previously Treated Non-Small Cell Lung Cancer (NSCLC). Value in Health. 26(12). S119–S120. 1 indexed citations

Cope, Shannon, Rachel Goldgrub, Dieter Ayers, et al.. (2019). Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer. Journal of Comparative Effectiveness Research. 8(10). 733–751. 6 indexed citations

Chau, Ian, Dung T. Le, Patrick A. Ott, et al.. (2019). Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. Gastric Cancer. 23(1). 133–141. 12 indexed citations

Korytowsky, Beata, et al.. (2018). Cost of Care in Advanced Non-Small Cell Lung Cancer (ANSCLC) in the Immuno-Oncology (IO) ERA: A Real-World Analysis of Early Data. Value in Health. 21. S122–S123.

Cope, Shannon, et al.. (2018). Approaches for Estimating the Comparative Efficacy of Treatments for Patients with Recurrent Small Cell Lung Cancer (SCLC) within Connected and Disconnected Networks of Evidence. Value in Health. 21. S16–S16. 1 indexed citations

10.

Santi, Irene, et al.. (2018). PRM157 - THE IMPACT OF LANDMARK RESPONSE ON OVERALL SURVIVAL: IMPLICATIONS FOR THE ECONOMIC EVALUATION OF IMMUNE-THERAPY (I-O) TREATMENT IN SMALL CELL LUNG CANCER (SCLC). Value in Health. 21. S383–S383. 2 indexed citations

11.

Jd, Miller, et al.. (2017). The Humanistic Burden of Microsatellite Instability-High (MSI-H) Colorectal Cancer (CRC) and Metastatic CRC (MCRC) Patients Treated with Subsequent Line Therapy: A Systematic Review. Value in Health. 20(9). A454–A454. 1 indexed citations

12.

Stenehjem, David D., Prianka Singh, Thomas Wısnıewskı, et al.. (2017). Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC): Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib. Value in Health. 20(9). A502–A503. 2 indexed citations

13.

Stenehjem, David D., et al.. (2016). Healthcare resource utilization (HCRU) in patients with advanced NSCLC in CheckMate 017 and 057 based on treatment-related (TR) adverse events (AEs). Annals of Oncology. 27. vi422–vi422. 1 indexed citations

14.

Blumenschein, George R., Jason C. Chandler, Edward B. Garon, et al.. (2016). PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC. Journal of Thoracic Oncology. 11(11). S307–S307. 4 indexed citations

15.

Hussein, Maen, Donald Richards, Brian Ulrich, et al.. (2016). ORAL01.02: Biopsies in Initial Diagnosis of Non–Small Cell Lung Cancer in US Community Oncology Practices: Implications for First-Line Immunotherapy. Journal of Thoracic Oncology. 11(11). S249–S250. 2 indexed citations

16.

Stenehjem, David D., et al.. (2015). Understanding The Impact Of Patient And Physician Preferences In Personalized Treatment For Melanoma Using A Discrete Choice Experiment. Value in Health. 18(7). A469–A470. 2 indexed citations

17.

Hirsch, Bradford R., Michael R. Harrison, Daniel J. George, et al.. (2014). Use of “Real-World” data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice. Medical Oncology. 31(9). 156–156. 7 indexed citations

18.

Molina, Ana M., Xun Lin, Beata Korytowsky, et al.. (2013). Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. European Journal of Cancer. 50(2). 351–358. 111 indexed citations

19.

Ishak, Jack, Juan W. Valle, Eric Van Cutsem, et al.. (2011). Overall Survival (OS) Analysis of Sunitinib (SU) after Adjustment for Crossover (CO) in Patients with Pancreatic Neuroendocrine Tumors (NET). Neuroendocrinology. 94. 27–28. 1 indexed citations

20.

Hensley, Martee L., Mark E. Robson, Noah D. Kauff, et al.. (2003). Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecologic Oncology. 89(3). 440–446. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact